Hepatic Fibrosis Mechanisms and Therapeutic Interventions

Hepatic fibrosis arises from chronic liver injury and represents a wound-healing response that has become maladaptive. Central to its progression is the activation of quiescent hepatic stellate cells, which transform into myofibroblast-like cells that overproduce extracellular matrix (ECM) components such as fibrillar collagens. This process is orchestrated by profibrotic mediators including transforming growth factor-beta, platelet-derived growth factor and inflammatory cytokines, as well as by crosstalk with resident macrophages, endothelial cells and infiltrating lymphocytes. Mechanical cues from the stiffening matrix further amplify stellate cell activation via integrin signalling, while alterations in matrix composition directly modulate growth-factor availability. Although persistent injury leads to cirrhosis and organ failure, early stages of fibrosis remain reversible through matrix degradation by metalloproteinases and resolution of inflammation. Current therapeutic strategies aim to halt or reverse scar formation by targeting inflammatory pathways, inhibiting stellate cell activation and proliferation, promoting ECM degradation, and mitigating oxidative stress. Novel approaches include antifibrotic small molecules repositioned from other fields, gene- and cell-based therapies to restore healthy tissue architecture, and microenvironmental engineering to normalise matrix mechanics. Together, these insights offer routes to arrest progression at subclinical stages and to promote functional liver regeneration.

Research from Nature Portfolio

Proteomic analyses of damaged liver have defined non-uniform alterations in ECM composition, revealing region-specific increases in collagens I, IV and V alongside reductions in elastin. These changes create a stiffer microenvironment that differentially regulates hepatocyte and biliary progenitor proliferation, highlighting spatial control of regeneration via matrix remodelling. Metabolomic profiling in a carbon-tetrachloride model has identified early perturbations in amino acid and tricarboxylic acid cycle metabolites, along with dysregulated sphingolipid and glycerophospholipid species. Several of these metabolites track the transition from mild fibrosis to advanced stages and show promise both as non-invasive biomarkers and as modulators of fibrogenic pathways. Meanwhile, preclinical evaluation of an orally available antifibrotic agent demonstrated marked attenuation of steatohepatitis-associated scarring in a mouse model, chiefly by preventing hepatocyte apoptosis and blunting downstream profibrotic signalling cascades. These studies collectively underscore the importance of matrix dynamics, metabolic rewiring and cell-survival pathways as interlinked targets for intervention.

Hepatic Fibrosis Mechanisms and Therapeutic Interventions publication trend

The graph below shows the total number of articles in hepatic fibrosis mechanisms and therapeutic interventions across all publications each year (not limited to Nature Index journals).

Technical terms

Hepatic stellate cell: A liver pericyte that, upon activation by injury or inflammation, differentiates into a myofibroblast-like cell responsible for collagen deposition.

Extracellular matrix (ECM): The network of structural proteins, glycoproteins and proteoglycans that provides mechanical support and biochemical cues to surrounding cells.

Transforming growth factor-beta (TGF-β): A cytokine that potently induces stellate cell activation, ECM synthesis and fibrogenic gene expression.

Matrix metalloproteinases (MMPs): A family of proteolytic enzymes that degrade ECM components and facilitate tissue remodelling.

Metabolomics: The comprehensive analysis of small-molecule metabolites in biological samples, used here to identify biomarkers and mechanistic pathways in fibrotic progression.

References

1. Combinatorial Microgels for 3D ECM Screening and Heterogeneous Microenvironmental Culture of Primary Human Hepatic Stellate Cells. Advanced Science (2024).
2. Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy. Frontiers in Cell and Developmental Biology (2021).
3. The alterations in the extracellular matrix composition guide the repair of damaged liver tissue. Scientific Reports (2016).
4. αv integrins: key regulators of tissue fibrosis. Cell and Tissue Research (2016).
5. Identification of key metabolic changes during liver fibrosis progression in rats using a urine and serum metabolomics approach. Scientific Reports (2017).
6. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis. Scientific Reports (2017).